LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 60 of 497
Next
>>
>
1476 to 1500 of 12420 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Relative Growth Rate After Treatment
BT-20	Celastrol	3.33	uM	LJP6	3	G08	72	hr	1097	420	3769	0.1114	-0.2534
BT-20	CGP60474	3.33	uM	LJP5	1	F02	72	hr	1097	547	3769	0.1451	-0.2059
BT-20	CGP60474	3.33	uM	LJP5	2	F02	72	hr	1097	588	3769	0.1560	-0.1906
BT-20	CGP60474	3.33	uM	LJP5	3	F02	72	hr	1097	645	3769	0.1711	-0.1692
BT-20	CGP60474	3.33	uM	LJP6	1	G02	72	hr	1097	547	3769	0.1451	-0.2059
BT-20	CGP60474	3.33	uM	LJP6	2	G02	72	hr	1097	481	3769	0.1276	-0.2306
BT-20	CGP60474	3.33	uM	LJP6	3	G02	72	hr	1097	522	3769	0.1385	-0.2153
BT-20	CHIR-99021	3.33	uM	LJP6	1	P14	72	hr	1097	3093	3769	0.8205	0.7468
BT-20	CHIR-99021	3.33	uM	LJP6	2	P14	72	hr	1097	3451	3769	0.9155	0.8808
BT-20	CHIR-99021	3.33	uM	LJP6	3	P14	72	hr	1097	3807	3769	1.0099	1.0140
BT-20	CP724714	3.33	uM	LJP5	1	A08	72	hr	1097	2856	3769	0.7577	0.6581
BT-20	CP724714	3.33	uM	LJP5	2	A08	72	hr	1097	2754	3769	0.7306	0.6200
BT-20	CP724714	3.33	uM	LJP5	3	A08	72	hr	1097	3117	3769	0.8269	0.7558
BT-20	CP466722	3.33	uM	LJP5	1	I08	72	hr	1097	3523	3769	0.9346	0.9077
BT-20	CP466722	3.33	uM	LJP5	2	I08	72	hr	1097	3449	3769	0.9150	0.8801
BT-20	CP466722	3.33	uM	LJP5	3	I08	72	hr	1097	3588	3769	0.9518	0.9321
BT-20	Crizotinib	3.33	uM	LJP5	1	A20	72	hr	1097	1422	3769	0.3772	0.1215
BT-20	Crizotinib	3.33	uM	LJP5	2	A20	72	hr	1097	1492	3769	0.3958	0.1477
BT-20	Crizotinib	3.33	uM	LJP5	3	A20	72	hr	1097	1786	3769	0.4738	0.2577
BT-20	Momelotinib	3.33	uM	LJP5	1	P08	72	hr	1097	2087	3769	0.5537	0.3704
BT-20	Momelotinib	3.33	uM	LJP5	2	P08	72	hr	1097	2655	3769	0.7043	0.5829
BT-20	Momelotinib	3.33	uM	LJP5	3	P08	72	hr	1097	2249	3769	0.5966	0.4310
BT-20	Dasatinib	3.33	uM	LJP5	1	D02	72	hr	1097	1048	3769	0.2780	-0.0184
BT-20	Dasatinib	3.33	uM	LJP5	2	D02	72	hr	1097	1326	3769	0.3518	0.0856
BT-20	Dasatinib	3.33	uM	LJP5	3	D02	72	hr	1097	1218	3769	0.3231	0.0452

|<
<<
Previous
Page 60 of 497
Next
>>
>
1476 to 1500 of 12420 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)